| UNITED STATES | |
| SECURITIES AND EXCHANGE COMMISSION | |
| Washington, D.C. 20549 | |
| Notice of Effectiveness | |
| Effectiveness Date: | March 30, 2026 4:00 P.M. |
| Form: | F-3 | ||||||
| |||||||
| UNITED STATES | |
| SECURITIES AND EXCHANGE COMMISSION | |
| Washington, D.C. 20549 | |
| Notice of Effectiveness | |
| Effectiveness Date: | March 30, 2026 4:00 P.M. |
| Form: | F-3 | ||||||
| |||||||
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 1/6/2025 | $23.00 | Buy | D. Boral Capital |
| 9/8/2023 | $14.50 | Buy | Alliance Global Partners |
| 1/5/2023 | $21.00 | Overweight | Cantor Fitzgerald |
Expands Nanox's growing network of U.S. distribution partnerships PETAH TIKVA, Israel, April 23, 2026 (GLOBE NEWSWIRE) -- Nano-X Imaging Ltd. (("Nanox", or the "Company", NASDAQ:NNOX), a leader in innovative medical imaging technology, today announced that its U.S.-based subsidiary, Nanox Impact Inc., has signed a distribution agreement with Radiology Oncology Systems, a U.S. provider of diagnostic imaging and oncology equipment solutions serving hospitals and clinics nationwide, to distribute its Nanox.ARC systems across the U.S. Under the terms of the agreement, Radiology Oncology Systems will support the commercial rollout of the Nanox.ARC, an FDA-cleared, multisource digital tomosynt
Howard's nationwide reach across healthcare and public sector markets expands Nanox's U.S. channel partner network to additional customer segments PETAH TIKVA, Israel, April 20, 2026 -- Nano-X Imaging Ltd. (("Nanox", or the "Company", NASDAQ:NNOX), a leader in innovative medical imaging technology, today announced a strategic commercial agreement with Howard Technology Solutions, a leading U.S.-based technology solutions provider with deep expertise in healthcare and a broad national footprint. The agreement will support the commercial rollout of the Nanox.ARC, an FDA-cleared, multisource digital tomosynthesis system that makes 3D imaging possible in more clinical settings, at a lower cost
Advanced commercialization in the US, signing multiple new customer and distribution agreements for Nanox.ARC and accelerated activities around Nanox.AI Management to host conference call and webcast Monday, April 20, 2026 at 8:30 AM ET Appointed new CFO effective August 1, 2026 PETAH TIKVA, Israel, April 20, 2026 (GLOBE NEWSWIRE) -- NANO-X IMAGING LTD (NASDAQ:NNOX) ("Nanox" or the "Company"), an innovative medical imaging technology company, today announced results for the fourth quarter ended December 31, 2025, and provided a business update. Recent Highlights: Generated $3.7 million in revenue in the fourth quarter of 2025, compared to $3.0 million in the fourth quarter o
4 - Nano-X Imaging Ltd. (0001795251) (Issuer)
D. Boral Capital initiated coverage of Nano-X Imaging with a rating of Buy and set a new price target of $23.00
Alliance Global Partners initiated coverage of Nano-X Imaging with a rating of Buy and set a new price target of $14.50
Cantor Fitzgerald initiated coverage of Nano-X Imaging with a rating of Overweight and set a new price target of $21.00
3 - Nano-X Imaging Ltd. (0001795251) (Issuer)
3 - Nano-X Imaging Ltd. (0001795251) (Issuer)
3 - Nano-X Imaging Ltd. (0001795251) (Issuer)
6-K - Nano-X Imaging Ltd. (0001795251) (Filer)
EFFECT - Nano-X Imaging Ltd. (0001795251) (Filer)
F-3/A - Nano-X Imaging Ltd. (0001795251) (Filer)
NEVE ILAN, Israel, May 03, 2021 (GLOBE NEWSWIRE) -- NANOX IMAGING LTD (NASDAQ:NNOX) ("Nanox" or the "Company"), an innovative medical imaging technology company, announced today the appointment of Moshe Shtengel as Chief Business Officer, effective May 2, 2021. Mr. Shtengel joins Nanox from Tuttnauer, a global manufacturer of sterilizers and infection control systems for medical institutions, where he served as Vice President of Global Sales, Marketing and Products. "Moshe is an extremely seasoned sales and business development executive with a proven track record of success and leadership in the medical field," stated Ran Poliakine, Chairman and Chief Executive Officer of Nanox. "As we
Advanced commercialization in the US, signing multiple new customer and distribution agreements for Nanox.ARC and accelerated activities around Nanox.AI Management to host conference call and webcast Monday, April 20, 2026 at 8:30 AM ET Appointed new CFO effective August 1, 2026 PETAH TIKVA, Israel, April 20, 2026 (GLOBE NEWSWIRE) -- NANO-X IMAGING LTD (NASDAQ:NNOX) ("Nanox" or the "Company"), an innovative medical imaging technology company, today announced results for the fourth quarter ended December 31, 2025, and provided a business update. Recent Highlights: Generated $3.7 million in revenue in the fourth quarter of 2025, compared to $3.0 million in the fourth quarter o
PETACH TIKVA, Israel, April 06, 2026 (GLOBE NEWSWIRE) -- NANO-X IMAGING LTD ((", Nanox", or the ", Company", , NASDAQ:NNOX), an innovative medical imaging technology company, today announced that it will report its financial results for the quarter ended December 31, 2025, before market open on Monday, April 20, 2026. Erez Meltzer, Chief Executive Officer and Acting Chairman, and Ran Daniel, Chief Financial Officer, will host a conference call to review these results and provide a business update beginning at 8:30 a.m. ET. Interested parties may register for the conference call using the following link: Nanox Q4 2025 Call The live webcast of the conference call may be accessed by using t
Management to host conference call and webcast Thursday, November 20, 2025, at 8:30 AM ET Company advances commercialization and is on track to meet year-end system deployment target PETAH TIKVA, Israel, Nov. 20, 2025 (GLOBE NEWSWIRE) -- NANO-X IMAGING LTD (NASDAQ:NNOX) ("Nanox" or the "Company"), an innovative medical imaging technology company, today announced results for the third quarter ended September 30, 2025, and provided a business update. Recent Highlights: Generated $3.4 million in revenue in the third quarter of 2025, compared to $3.0 million in the third quarter of 2024.Acquired 100% of the stock of Vaso Healthcare IT, a provider of healthcare information technologies solu
SC 13G/A - Nano-X Imaging Ltd. (0001795251) (Subject)
SC 13G - Nano-X Imaging Ltd. (0001795251) (Subject)
SC 13G/A - Nano-X Imaging Ltd. (0001795251) (Subject)